Zuellig pledges to invest over S$50m in S'pore centre

Singapore

ZUELLIG Pharma plans to work with Singapore's National Healthcare Group to develop predictive models for early health screening, and carry out treatment cost versus quality analysis, using data analytics. It announced this on Wednesday, following an investment commitment of more than S$50 million over the next five years in its new Singapore-based innovation centre.

The centre, known as Zuellig Health Solutions (ZHS), will develop data, digital and disease management solutions. These are meant to help doctors develop more effective treatment plans, support patients managing chronic conditions, and help payors manage healthcare costs, it said.